*Yuzy Fauzyah¹, Chikako Ono¹, Takasuke Fukuhara¹, Asuka Sato¹, Takuma Izumi¹, Shiho Torii¹, Takuya Yamamoto¹, Yuhei Morioka¹, Yoshiharu Matsuura¹ (1. Department of Molecular Virology Research Institute for Microbial Diseases Osaka University)

*Yuichi Akahori¹, Machiko Sasai^1,2, Hitomi Okamura^1,2, Mizuki Oshima³, Koichi Watashi³, Takaji Wakita³, Yasunori Nio⁴, Makoto Hijikata^1,2 (1. Laboratory of Tumor Viruses, Institute for Frontier Life and Medical Sciences, Kyoto University, 2. Graduate School of Biostudies, Kyoto University, 3. Department of Virology II, National Institute of Infectious Diseases, 4. Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited)

*Mizuki Oshima^1,2, Masashi Iwamoto¹, Kousho Wakae¹, Hideki Aizaki¹, Kouji Kuramochi², Masamichi Muramatsu¹, Takaji Wakita¹, Koichi Watashi^1,2 (1. Department of Virology II, National Institute of Infectious Diseases, 2. Tokyo University of Science Graduate School of Science and Technology)

*Midori Takeda¹, Masaya Sugiyama², Masanori Baba³, Masashi Mizokami², Yasuhito Tanaka⁴, Nobuyuki Kato⁵, Masanori Ikeda¹ (1. Division of Biological Information Technology, Joint Research Center for Human Retrovirus Infection, Kagoshima University, 2. Department of Genome Medical Sciences Project, Research Institute, National Center for Global Health and Medicine, 3. Division of Antiviral Chemotherapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University, 4. Department of Virology, Graduate School of Medical Sciences, Nagoya City University, 5. Department of Tumor virology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University)